Company intelligence / Profile preview

Lamassu Pharma

Durham, North Carolina, United Stateslamassupharma.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

The company has received FDA approval to initiate Phase 1/2a clinical trials for its cancer treatment protocol. Their pancreatitis treatment is in Phase 2. RABI-767, their pancreatic cancer therapeutic, was brought from research to trials in under 1.5 years.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Cleveland ClinicMayo ClinicArrivo BioVentures (for pancreatitis)unidentified major European pharmaceutical company

Beyond the preview

Go deeper on Lamassu Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lamassu Pharma.